Dresbuxelimab

佐斯利单抗

Report date: 2026/03/10 20:00:16

Base Information

Drug NameDresbuxelimab
Drug Alias NameAK-119
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of Action5'-nucleotidase inhibitors
Targets5'-nucleotidase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursIdiopathic Pulmonary Fibrosis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNew ZealandAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAkeso Pharmaceuticals Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesAkeso Pharmaceuticals IncAkesobio Australia Pty LtdZhongshan Akeso Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursIdiopathic Pulmonary Fibrosis +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A